Results 251 to 260 of about 43,876 (313)

Procognitive Potential of Neuroprotective Triazine 5-HT₆ Receptor Antagonists Tested on Chronic Activity In Vivo in Rats: Computer-Aided Insight into the Role of Chalcogen-Differences on the Pharmacological Profile. [PDF]

ACS Chem Neurosci
Jastrzębska-Więsek M, Garbo S, Cios A, Wilczyńska-Zawal N, Partyka A, Honkisz-Orzechowska E, Żesławska E, Handzlik J, Mordyl B, Głuch-Lutwin M, Raucci A, Hittinger M, Starek M, Dąbrowska M, Nitek W, Karcz T, Skórkowska A, Gdula-Argasińska J, Czarnota-Łydka K, Pyka P, Szymańska E, Kucwaj-Brysz K, Zwergel C, Wesołowska A, Battistelli C, Handzlik J.   +25 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Donepezil

Drugs & Aging, 1997
Donepezil is a specific and potent acetylcholinesterase inhibitor according to in vitro data. It displays primarily noncompetitive inhibitory activity. In vivo, donepezil inhibited acetylcholinesterase activity in human erythrocytes and increased extracellular acetylcholine levels in the cerebral cortex and hippocampus of the rat.
Paul Benfield, Harriet M. Bryson
  +8 more sources

Donepezil HCl Liposomes: Development, Characterization, Cytotoxicity, and Pharmacokinetic Study

AAPS PharmSciTech, 2022
The current research work aims to study the pharmacokinetic and nasal ciliotoxicity of donepezil liposome–based in situ gel to treat Alzheimer’s disease.
Amarjitsing Rajput, Shital Butani
semanticscholar   +1 more source

Compared of efficacy and safety of high-dose donepezil vs standard-dose donepezil among elderly patients with Alzheimer’s disease: a systematic review and meta-analysis

Expert Opinion on Drug Safety, 2022
Background Donepezil is a first-line drug for the treatment of Alzheimer’s disease (AD). However, there are no meta-analyses on efficacy and safety of high-dose versus standard-dose donepezil in the treatment of moderate-to-severe AD. Research Design and
Hecheng Wang, Y. Zong, Yanshuo Han, Jing-ya Zhao, Hongqun Liu, Yong Liu   +5 more
semanticscholar   +1 more source

Bradycardia Due to Donepezil in Adults: Systematic Analysis of FDA Adverse Event Reporting System

Journal of Alzheimer's Disease, 2021
Background: Bradycardia is a physiological condition characterized by a decrease in heart rate and is a side effect of many drug classes. Bradycardia has been reported as an adverse event for patients receiving donepezil for Alzheimer’s disease (AD ...
Robert Morris, Hunter Luboff, Rahul P Jose, Kyle Eckhoff, Kun Bu, Minh Pham, Dekai Rohlsen-Neal, Feng Cheng   +7 more
semanticscholar   +1 more source

Enhancing Therapeutic Efficacy of Donepezil by Combined Therapy; A Comprehensive Review.

Current pharmaceutical design, 2020
Combination therapy involving different therapeutic strategies mostly provides more rapid and effective results as compared to monotherapy in diverse areas of clinical practice.
Xi Rong, Liwei Jiang, Meijie Qu, Syed Shams ul Hassan, Zongchao Liu   +4 more
semanticscholar   +1 more source